Anti-otub1 (57-70)

Not available outside of the UK & Ireland.

Application

Yale Center for High Throughput Cell Biology IF-tested antibodies. Each antibody is tested by immunofluorescence against HUVEC cells using the Yale HTCB IF protocol. To learn more about us and Yale Center for High Throughput Cell Biology partnership, visit sigma.com/htcb-if.

Biochem/physiol Actions

OTUB1 (OTU domain-containing ubiquitin aldehyde binding protein 1) expression helps to predict the prognosis of hepatocellular carcinoma (HCC)in patients. It can control the T-cell anergy by improving the degradation of the E3 ligase gene related to anergy in lymphocytes (GRAIL).

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

OTUB1 (OTU domain-containing ubiquitin aldehyde binding protein 1), a deubiquitinating enzyme (DUB) is a member of the ovarian tumor (OTU) domain protease superfamily. It is expressed in kidney, intestine, brain, liver and lung. This gene is located on human chromosome 11q13.1.

Immunogen

synthetic peptide corresponding to amino acids 57-70 of human OTUB1

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.